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DNA sequencing methods have identified a large and growing number of sequence 
variants that are associated with disease but are of unknown biological significance and 
remain unclassified with regard to their pathogenic role. A large fraction of these 
unclassified variants (UVs), estimated between 15 and 50%, could influence RNA splicing. 
After two decades of basic research on RNA splicing, which have led to a detailed picture 
of the biochemistry of this process, the impact of splicing defects in human genetics still 
appears to be underestimated. Moreover, the interpretation of mutations inducing splicing 
defects remains difficult for the majority of clinical molecular geneticists, mainly because 
of the complexity of RNA splicing regulation, as illustrated schematically in Figure 1. The 
best known splicing mutations are those that affect sequences at the exon/intron boundaries 
and induce exon skipping, or create new exon boundaries, or activate cryptic splice sites. 
However, more subtle effects on splicing can be induced by sequence changes that affect 
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exonic or deep intronic splicing regulatory elements. Thus, intronic as well as exonic 
changes, including those that are silent at the translation level, can induce splicing 
mutations. Deep intronic changes can create pseudoexons. The interpretation of splicing 
mutations often raises questions. For example, the predicted consequences of splicing 
mutations at the protein level are usually frameshifts or in–frame deletions/insertions and 
thus are expected to be similar to the consequences of truncating mutations or 
deletions/insertions caused by other mechanisms, such as insertions/deletions or 
rearrangements at the gene level. But splicing mutations often show the peculiar features of 
incomplete expressivity and of tissue specificity 1. 
 
These and other related questions were addressed at the “Splicing and genetic diseases” 
workshop, sponsored by EURASNET (the European Alternative Splicing Network, 
www.eurasnet.info) in Paris, October 1st and 2nd , 2009, which brought together the worlds 
of clinical molecular geneticists and basic researchers working on alternative splicing. 
 
The conference discussed examples of UVs detected in molecular diagnostic activities 
on several genes involved in mendelian diseases, such as Neurofibromatosis type 1 and 
Tuberous sclerosis (Diana Baralle), Spinal muscular atrophy (Alexandra Martins, Rouen), 
susceptibility to Breast/ovarian cancers (Claude Houdayer, Paris; Sylvie Mazoyer, Lyon), 
hereditary colon cancers (Mario Tosi), Usher syndrome and Duchenne and Becker 
muscular dystrophy (Sylvie Tuffery-Giraud, Montpellier), and Cystic fibrosis (Abdel 
Aissad and Pascale Fanen, Créteil, France). The examples showed that the effect of 
mutations within the splice sites can be predicted rather accurately. However, predicting the 
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possible effects on splicing of UVs located at deep intronic positions or at internal positions 
of exons can be very difficult. Exonic UVs can affect splicing regulatory elements and 
induce splicing defects instead of, or in addition to, producing functionally relevant protein 
changes. It is therefore currently not possible to set general guidelines for the prediction of 
the effects of UVs on splicing and functional assays are necessary to validate 
bioinformatics predictions or to improve them.  
 
Patient RNA analyses are currently performed only in a minority of molecular diagnostic 
laboratories. Moreover, the relevant mRNA is sometimes not available, because the gene is 
expressed only in specialized tissues. Therefore, current efforts are aimed on one hand at 
improving bioinformatics predictions of the effects of UVs on splicing and, on the other 
hand, at optimizing ex vivo functional splicing assays based on the use of patient DNA and 
hybrid minigenes. 1,2 To rapidly test mutations in vivo, Stefan Stamm described a high-
throughput cloning method for splicing reporters. This method circumvents the need of 
suitable restriction sites and permits the functional analysis of sequence segments ranging 
from small exons to large gene portions or entire genes. 3 
  
Stefan Stamm also described screening methods and rational design for developing 
substances that change splice site selection and could be used in therapies based on the 
somatic correction of splicing defects. Support for current therapeutic strategies based on 
the modulation of splicing, using drugs 4 or antisense oligonucleotides 5 was also provided 
at the workshop by a report on the natural occurrence of enhanced inclusion of SMN2 exon 
7, which correlates with an attenuated form of SMA in several patients (A. Martins). This 
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positive modulation of exon 7 splicing is induced by a rare SMN2 variant in a previously 
unrecognized composite splicing regulatory element in the centre of exon 7. 6 
 
During the conference, analysis software for human mutations was presented (André 
Blavier, Interactive Biosoftware, Rouen; François-Olivier Desmet and Christophe Béroud, 
Montpellier). Algorithms are quite accurate in predicting the effects of the variants that are 
located at or near the exon boundaries and of those that generate new splice sites. Therefore 
bioinformatics predictions can be used for establishing priorities for analyzing UVs of the 
BRCA genes at the patient RNA level (Claude Houdayer). However the effects on splicing 
of deep intronic variants and of most exonic variants cannot be predicted by the current 
software, and closer interactions between experts working in basic research on splicing and 
developers of software are needed to improve the accuracy of bioinformatics predictions. 
 
Clinical geneticists would greatly benefit from the development of criteria for the 
classification of UVs, including those that may affect splicing. 7,8 Recent achievements 
towards establishing such criteria were discussed during the workshop by Sean Tavtigian 
(Lyon, France and Salt Lake City, USA). Statistical methods have been developed to 
combine data across different data types in order to obtain an integrated posterior 
probability that a variant is pathogenic. These methods have been applied to the missense 
changes of the BRCA1 and BRCA2 genes. Work in progress shows that it should soon be 
possible to integrate predictions of splice site changes into the calculation of these posterior 
probabilities. However, it will be difficult to account for exonic variants in general, because 
they cannot be predicted accurately by current algorithms. 
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Splicing is not only changed by germline mutations. It can also be altered as a consequence 
of somatic mutations especially in cancer. Didier Auboeuf (Lyon, France) discussed 
multiple changes of alternative splicing in tumor progression that can be detected by exon 
array analyses. This work identified alternative exons associated with metastatic potential 
in a murine model of mammary tumours. Moreover, a set of alternative splicing events 
identified in this model system was shown to have prognostic value in breast cancer 
patients. 
 
The conference showed that tight, cooperative interaction between clinical geneticists and 
molecular biologists working on splicing has mutual benefits. Both worlds can learn from 
each other: each human mutation that gives a phenotype is an “experiment of nature” that 
shows how splicing is regulated. Reversely, basic research on splicing can help by 
predicting whether mutations have an effect on splicing and give therefore insight into the 
disease pathology. Additional meetings are needed to foster the interactions, across the 
boundaries of particular genetic diseases, between RNA splicing experts and clinical 
molecular geneticists and also to discuss practical issues of the interpretation of splicing 
mutations found in molecular diagnostic laboratories. The authors of this report are 
organizing another European workshop on splicing and disease, which is expected to take 
place in France in the fall of 2010. 
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Titles and legends to figures 
 
Figure 1: Schematic overview over disease mechanisms. 
A hypothetical pre-mRNA is shown. Exons are indicated as boxes, introns as lines. The 
splicing pattern is depicted by dashed lines. Proteins that aid in exon recognition are 
indicated as circles. Only three proteins are shown for simplicity. Most of the pre-mRNA 
will be coated with proteins. An exonic regulatory element is shown by a green rectangle in 
the alternative exon. Mutations in this exon can alter the usage of the alternative exon and 
lead to a human disease, even if the mutation does not change the predicted reading frame. 
The 3’ and 5’ splice sites of the alternative exon (3’ss and 5’ss, respectively) are shown by 
solid pointed arrows. Mutations of these splice sites generally change exon usage and in 
most cases studied abolish the use of the alternative exon. In addition, intronic mutations 
that are indicated by open arrows can generate new exons, if these mutations generate new 
splice sites. An intronic mutation m1 that is close to the authentic 5’ splice site can lead to 
the generation of a cryptic exon that is indicated by a striped, smaller box and its splicing 
pattern is indicated by a dotted line. The deep intronic mutation m2 can lead to the 
formation of a new exon if it is close enough to a cryptic splice site, indicated by a round 
arrow. For simplicity, only mutations leading to new 5’ splice sites are shown, but new 3’ 
splice sites can also be generated by new mutations. 
 
 

